March 12th 2024
The BCR-ABL tyrosine kinase inhibitor TERN-701 has been granted an orphan drug designation from the FDA for the treatment of chronic myeloid leukemia.
December 12th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Neratinib Shows Promise for HER2-Positive Breast Cancer in I-SPY 2 Trial
April 10th 2014The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer.
Read More
Ibrutinib as Treatment for Patients with CLL
April 7th 2014Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ibrutinib, which was recently approved for patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy.
Watch
CDX-1401 in Combination with Decitabine in Patients with MDS
April 1st 2014Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses a phase I trial that studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia
Watch
A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
January 24th 2014Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
Watch
Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLL
January 8th 2014Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.
Watch
A Preview of the 2013 ASH Annual Meeting
December 5th 2013Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.
Read More
Frontline Obinutuzumab (Gazyva) Approved for CLL
November 1st 2013Obinutuzumab (Gazyva) plus chlorambucil has been approved by the FDA as a first-line treatment for patients with CLL, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.
Read More
Ponatinib Trial Discontinued Following Occurrence of Arterial Thrombotic Events
October 21st 2013A phase III EPIC trial exploring ponatinib (Iclusig) in untreated patients with chronic myeloid leukemia (CML) has been discontinued. The decision comes following a high occurrence of arterial thrombotic events, according to a statement released by Ariad Pharmaceuticals, Inc., the company developing the drug.
Read More
FDA Grants Breakthrough Therapy Designation for Volasertib
September 18th 2013The FDA has granted a Breakthrough Therapy designation to the novel PLK1 inhibitor volasertib in combination with LDAC for its potential as a treatment for patients with untreated AML who are ineligible for intensive remission induction therapy.
Read More